About: Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Creator	Gordienko, Lyudmila Kruglova, Oksana Moroz, Larisa Prishliak, Oleksandra Shostakovich-Koretska, Lyudmila Tieroshyn, Vadim
Source	PMC
abstract	The acute diarrhea is a wide-spread disease. The prescription of enterosorbents is appropriate as a primary measure for the treatment of the acute diarrhea for effective prevention of the fluid and electrolyte loss, as well as method for symptom relief of the attack of the disease. Aim of the study - the antidiarrheal efficacy and safety study of high-dispersion silicon dioxide enterosorbent in tablet dosage form in patients with acute diarrhea. This was randomized, double-blind, placebo-controlled, 4-center study. Acute diarrhea was defined as three and more episodes of watery stool per day either during 48 hours or less before study entry in the patients having normal stool recently. It has been postulated that symptoms and signs of acute diarrhea have to be caused by direct infection of the gastrointestinal tract and did not associated with moderate-to-severe systemic states. 144 patients with established acute diarrhea were randomized into treatment group (enterosorbent “Carbowhite”, n = 120) or placebo group. Date collection including severity diarrhea, systemic symptoms was performed at baseline and daily during 7 days. Stool examination and serological assay were performed at baseline. The primary end points were declared as time to complete recovery from acute diarrhea. It has been found that the use of the siliceous enterosorbent (“Carbowhite”) allowed to reduce (p < 0.001) the treatment period averagely for 0.9 days (95% confidence interval 0.5–1.2 days) in comparison with placebo. Data of safety monitoring has revealed that both patient groups had negative stool culture, while initiation of antibiotic treatment was run more frequently in placebo group (8.3%) compared to investigational product group (4.1%, P = 0.044). The siliceous enterosorbent “Carbowhite” was well tolerated and reduced the recovery time of the acute episode of the diarrhea in the clinically significant form.
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.1038/s41598-020-62386-0
bibo:pmid	32286322
has license	cc-by
sha1sum (hex)	78451683ac6fe46705cc3b44072a81d9c57b1b4d
schema:url	https://doi.org/10.1038/s41598-020-62386-0
resource representing a document's title	Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
has PubMed Central identifier	PMC7156649
has PubMed identifier	32286322
schema:publication	Sci Rep
resource representing a document's body	covid:78451683ac6fe46705cc3b44072a81d9c57b1b4d#body_text
is schema:about of	named entity 'diarrhea' named entity 'recovery' named entity 'placebo-controlled' named entity 'randomized' named entity 'diarrhea' named entity 'efficacy' named entity 'baseline' named entity 'double-blind' named entity 'recovery' named entity 'antidiarrheal' named entity 'acute' named entity 'diarrhea' named entity 'STOOL CULTURE' named entity 'PRODUCT GROUP' named entity 'FOUND' named entity 'INVESTIGATIONAL PRODUCT' named entity 'PATIENT' named entity 'STATES' named entity 'CAUSED BY' named entity 'SYSTEMIC' named entity 'RANDOMIZED' named entity '044' named entity 'ELECTROLYTE' named entity 'group' named entity 'study' named entity 'diarrhea' named entity 'negative' named entity 'signs' named entity 'defined' named entity 'effective' named entity 'systemic symptoms' named entity 'compared' named entity 'reduced' named entity 'diarrhea' named entity 'placebo' named entity 'disease' named entity 'Double' named entity '1.2' named entity 'Stool examination' named entity 'acute episode' named entity 'diarrhea' named entity 'gastrointestinal tract' named entity 'siliceous' named entity '0.9' named entity 'placebo group' named entity 'Diarrhea' named entity 'placebo-controlled' named entity 'adverse reactions' named entity 'placebo' named entity 'silicon dioxide' named entity 'defecation' named entity 'silicon dioxide' named entity 'diarrhea' named entity 'pathogens' named entity 'pus' named entity 'body weight' named entity 'diarrhea' named entity 'sample size' named entity 'placebo' named entity 'denaturation' named entity 'placebo group' named entity 'adsorb' named entity 'statistically significant' named entity 'stool culture' named entity 'therapeutic approaches' named entity 'diarrhea' named entity 'placebo' named entity 'diarrhea' named entity 'antibiotic treatment' named entity 'salmonellosis' named entity 'placebo effect' named entity 'diarrhea' named entity 'diarrhea' named entity 'SARS' named entity '0.9' named entity 'placebo'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software